Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
New Drugs Shine But Biosimilars Blunt Roche Revenue Rise
MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.
Silence Seeks Share Of Alnylam RNAi Success In Legal Action
The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.
Consolidation in Generics Sector As Impax Merges With Amneal
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
Roche Goes Back To Nature With Warp Drive Antibiotic Pact
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
European Approval Recommendation Delayed Again For Roche’s Ocrevus
No European approval recommendation for Roche multiple sclerosis drug Ocrevus but the Swiss major tells Scrip it is hopeful of getting approval within four months.